

115TH CONGRESS 2D SESSION

H. R. 1660

AN ACT

- To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.
 - 1 Be it enacted by the Senate and House of Representa-
 - ${\it 2\ tives\ of\ the\ United\ States\ of\ America\ in\ Congress\ assembled},$

1 SECTION 1. SHORT TITLE.

- This Act may be cited as the "Global Health Innova-
- 3 tion Act of 2017".

4 SEC. 2. ANNUAL REPORT.

- 5 (a) IN GENERAL.—Not later than 180 days after the
- 6 date of the enactment of this Act, and annually thereafter
- 7 for a period of 4 years, the Administrator of the United
- 8 States Agency for International Development shall submit
- 9 to Congress a report on the development and use of global
- 10 health innovations in the programs, projects, and activities
- 11 of the Agency.
- 12 (b) Matters To Be Included.—The report re-
- 13 quired by subsection (a) shall include the following:
- 14 (1) A description of—
- 15 (A) the extent to which global health inno-
- vations described in subsection (a) include
- drugs, diagnostics, devices, vaccines, electronic
- and mobile health technologies, and related be-
- 19 havior change and service delivery innovations;
- (B) how innovation has advanced the
- Agency's commitments to achieving an HIV/
- AIDS-free generation, ending preventable child
- and maternal deaths, and protecting commu-
- 24 nities from infectious diseases, as well as
- 25 furthered by the Global Health Strategic
- 26 Framework;

| 1 | (C) how goals are set for health product |
|----|---|
| 2 | development in relation to the Agency's health- |
| 3 | related goals and how progress and impact are |
| 4 | measured towards those goals; |
| 5 | (D) how the Agency's investments in inno- |
| 6 | vation relate to its stated goals; and |
| 7 | (E) progress made towards health product |
| 8 | development goals. |
| 9 | (2) How the Agency, both independently and |
| 10 | with partners, donors, and public-private partner- |
| 11 | ships, is— |
| 12 | (A) leveraging United States investments |
| 13 | to achieve greater impact in health innovation; |
| 14 | (B) engaging in activities to develop, ad- |
| 15 | vance, and introduce affordable, available, and |
| 16 | appropriate global health products; and |
| 17 | (C) scaling up appropriate health innova- |
| 18 | tions in the development pipeline. |
| 19 | (3) A description of collaboration and coordina- |
| 20 | tion with other Federal departments and agencies, |
| 21 | including the Centers for Disease Control and Pre- |
| 22 | vention, in support of global health product develop- |
| 23 | ment, including a description of how the Agency is |
| 24 | working to ensure critical gaps in product develop- |

ment for global health are being filled.

25

| 1 | (4) A description of how the Agency is coordi- | | | | | |
|---|--|--|--|--|--|--|
| 2 | nating and aligning global health innovation activi- | | | | | |
| 3 | ties between the Global Development Lab, the Cen- | | | | | |
| 4 | ter for Accelerating Innovation and Impact, and the | | | | | |
| 5 | Bureau for Global Health. | | | | | |
| | Passed the House of Representatives January 18 | | | | | |

Attest:

2018.

Clerk.

115TH CONGRESS H. R. 1660

AN ACT

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.